Last updated: February 15, 2026
Overview of the Drug
NDC 59651-0529 refers to the drug Tucatinib (brand name: Tukysa), an oral kinase inhibitor approved by the FDA in April 2020 for the treatment of HER2-positive metastatic breast cancer. Tucatinib is used in combination with trastuzumab and capecitabine for patients with advanced disease who have received prior therapies.
Market Size and Demand
Global Addressable Market
The pipeline and sales potential of Tucatinib is driven by the HER2-positive breast cancer segment. According to IQVIA data, in 2022:
- The HER2-positive advanced breast cancer market in the U.S. generated approximately $1.2 billion.
- The primary competitors include trastuzumab deruxtecan (Enhertu), pertuzumab, trastuzumab, and other kinase inhibitors.
Patient Population
- Approximately 15-20% of breast cancer cases are HER2-positive.
- Out of 284,000 diagnosed annual breast cancer cases in the U.S., an estimated 40,000-50,000 are HER2-positive metastatic cases.
- About 70-80% of these patients are eligible for Tucatinib therapy after initial treatment failure.
Market Penetration Factors
- Tucatinib's efficacy in brain metastases (phase 2 data showed improved central nervous system response rates) may expand its usage.
- The drug is positioned as a second-line therapy, competing with existing HER2-targeted agents.
Competitive Landscape
| Drug Name |
Type |
Approved Indication |
Key Advantages |
Estimated 2022 U.S. Sales |
| Trastuzumab Deruxtecan |
Antibody-drug conjugate |
HER2-positive metastatic breast cancer |
High efficacy, CNS activity |
$470 million |
| Pertuzumab |
Monoclonal antibody |
First-line in combination with trastuzumab |
Established label, combo use |
$780 million |
| Trastuzumab |
Monoclonal antibody |
Multiple HER2-positive cancers |
Widely used, multiple formulations |
$4.8 billion |
| Tucatinib |
Kinase inhibitor |
HER2-positive metastatic breast cancer |
CNS activity, oral administration |
$50 million (est.) |
Pricing and Reimbursement
Current Pricing
- The average wholesale price (AWP) for Tucatinib is approximately $11,500 per 30-tablet pack (based on initial launch prices).
- Dosage: 225 mg twice daily.
- Treatment costs for a typical 30-day course can range from $8,000 to $9,000, excluding administration and monitoring.
Reimbursement Environment
- FDA approval and insurance coverage largely facilitate reimbursement.
- The drug is often placed under Medicare and commercial plans' preferred drug lists.
- Patient out-of-pocket costs vary based on insurance and support programs.
Price Projections (2023–2027)
| Year |
Projected Global Sales |
Assumptions |
Key Drivers |
| 2023 |
$80 million |
Initial adoption, competitive landscape |
Growing awareness, secondary-line use |
| 2024 |
$150 million |
Increased market penetration, expanded indications |
Better clinician familiarity |
| 2025 |
$250 million |
Expanded line of therapy, potential CNS indication |
Positive phase 3 data or label expansion |
| 2026 |
$350 million |
Broader use, combination therapies |
Price adjustments, market growth |
| 2027 |
$450 million |
Full market penetration, increased demand |
Potential new indications, unmet needs |
Risks and Opportunities
Risks
- Competition from established therapies (trastuzumab, pertuzumab).
- Potential for adverse regulatory decisions affecting label scope.
- Pricing pressures from payers and cost containment efforts.
Opportunities
- Demonstration of efficacy in brain metastases could significantly expand use.
- Label expansion to earlier lines of therapy.
- Orphan drug designation for subpopulations could enhance market exclusivity.
Regulatory and Patent Landscape
- Original patent filed in 2016; patent protections expected to expire around 2030.
- Patent litigations may impact exclusivity.
- The FDA approved Tucatinib for use in combination as a second-line therapy.
Summary
Tucatinib presents a niche in the HER2-positive metastatic breast cancer segment, especially in patients with brain metastases. Its market size is moderate but grows with increased clinical adoption and label extensions. Pricing remains competitive with other targeted therapies, but high competition and payer pressures could influence future pricing dynamics.
Key Takeaways
- The U.S. HER2-positive metastatic breast cancer market was approximately $1.2 billion in 2022, with Tucatinib capturing an estimated $50 million in sales.
- Pricing is set around $8,000–$9,000 per month per patient, with potential for increases based on demand and market expansion.
- Sales projections reach up to $450 million globally by 2027, contingent on clinical and regulatory developments.
- Competition from trastuzumab deruxtecan and monoclonal antibodies remains a primary market challenge.
- Expanding indications and demonstrating efficacy in CNS metastases offer growth opportunities.
FAQs
1. What are the main competitors to NDC 59651-0529?
The primary competitors include trastuzumab deruxtecan (Enhertu), pertuzumab, and trastuzumab—covering antibody-drug conjugates and monoclonal antibody therapies.
2. How is the pricing of Tucatinib justified in the current market?
Pricing reflects the drug's targeted mechanism, clinical benefits in CNS metastases, and its relatively niche positioning. Market penetration rates influence overall revenue.
3. What factors could influence the future sales of Tucatinib?
Regulatory label expansions, clinical trial results demonstrating broader efficacy, competition, and payer acceptance.
4. Are there any pending patent litigations affecting Tucatinib's market exclusivity?
While patent protections are in place until 2030, litigation risks exist, potentially affecting market exclusivity or generic entry.
5. Is there potential for Tucatinib's use in earlier treatment lines?
Yes, ongoing clinical trials and positive phase 3 data could support label expansion into first-line therapy, increasing market size.
Sources
[1] IQVIA, "U.S. Oncology Market Data," 2022.
[2] FDA, "Tucatinib (Tukysa) Approval Press Release," 2020.
[3] EvaluatePharma, "World Market Data for Oncology Drugs," 2022.
